Induction of local angiotensin II-producing systems in stenotic aortic valves  by Helske, Satu et al.
I
P
S
K
M
H
R
v
d
o
l
t
(
T
p
t
h
a
r
t
p
M
a
b
H
f
a
Journal of the American College of Cardiology Vol. 44, No. 9, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Pnduction of Local Angiotensin II-
roducing Systems in Stenotic Aortic Valves
atu Helske, MD,* Ken A. Lindstedt, PHD,* Mika Laine, MD, PHD,† Mikko Mäyränpää, MD,*
alervo Werkkala, MD, PHD,‡ Jyri Lommi, MD, PHD,§ Heikki Turto, MD, PHD,§
arkku Kupari, MD, PHD,§ Petri T. Kovanen, MD, PHD*
elsinki, Finland
OBJECTIVES The purpose of this study was to investigate the expression of angiotensin II (Ang
II)-producing enzyme systems in normal and stenotic aortic valves.
BACKGROUND Chronic inflammation and fibrosis are involved in the pathogenesis of aortic stenosis (AS),
but the detailed molecular mechanisms of this atherosclerosis-like process remain obscure.
Angiotensin II, a powerful mediator of inflammation and fibrosis, may participate in AS
progression.
METHODS Stenotic aortic valves (n  86) were obtained from patients undergoing valve replacement
surgery, and control valves (n  11) were obtained from patients undergoing cardiac
transplantation. Angiotensin-converting enzyme (ACE) and mast cell (MC)-derived chy-
mase were quantified by reverse-transcription polymerase chain reaction, autoradiography,
and immunostaining. The MCs, macrophages, and T lymphocytes were detected by
immunohistochemistry, and angiotensin II type 1 receptor (AT-1R) by autoradiography.
RESULTS Compared with control valves, stenotic aortic valves showed a significant increase in both
messenger ribonucleic acid (mRNA) (p 0.001) and protein (p 0.001) expression of ACE,
which colocalized with macrophages. Similarly, the expression of AT-1R protein and
chymase mRNA and protein was upregulated (p  0.001), and the number of MCs was
six-fold higher in stenotic than in normal valves. The MCs were associated with the calcified
areas, and—in contrast to control valves—showed an increased degree of degranulation, a
prerequisite for chymase secretion and action.
CONCLUSIONS Angiotensin-converting enzyme and chymase, two Ang II-forming enzymes, are locally
expressed in aortic valves, and owing to infiltration of macrophages and MCs, are further
upregulated in stenotic valves. These novel findings, implicating chronic inflammation and an
increased expression of local Ang II-forming systems, suggest that therapeutic interventions
aiming at inhibiting these processes may slow AS progression. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.0541859–66) © 2004 by the American College of Cardiology Foundation
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oecent studies have demonstrated that stenotic aortic
alves, instead of merely being the result of a passive
egeneration, show similarities with the active pathobi-
logy of atherosclerosis. These include infiltration of T
ymphocytes and macrophages as evidence of inflamma-
ion (1–3), and the accumulation of oxidized lipoproteins
4) and mediators of ossification and calcification (5,6).
he idea of aortic stenosis (AS) as an atherosclerosis-like
rocess is supported by epidemiologic studies showing
hat the development of this disease is associated with
ypertension, diabetes, smoking, male gender, advancing
ge, and hypercholesterolemia (7,8). There are also ret-
ospective data suggesting that the use of statins may slow
he progression of valve stenosis (9,10). Recently, the
resence of angiotensin-converting enzyme (ACE) was
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ccepted July 28, 2004.dentified in stenotic but not in normal aortic valves (11).
he authors suggest that ACE enters the stenotic valve
esions from the circulation bound to and carried by
ow-density lipoprotein (LDL) particles. Whether ACE
s also locally produced in the valvular tissue is at present
nknown.
Angiotensin II (Ang II), the enzymatic product of
CE, is expressed in strategically relevant sites of human
therosclerotic plaques and may participate in the inflam-
atory process within the vascular wall (12). Because
ng II is an important mediator of inflammation and
brosis (13–17), it may play a role also in the pathogen-
sis of AS. In addition to ACE, the major Ang II-
orming enzyme, the mast cell (MC)-derived neutral
rotease, chymase, also contributes to Ang II formation
18). Mast cells are bone marrow-derived inflammatory
ells, originally linked to allergies and subsequently to
any inflammatory processes, as well as to lipoprotein
etabolism (19). The influence of MCs in the process of
S has not been evaluated previously, nor has the effect
f MC chymase, which is stored in the secretory granules
f these cells and released during their activation and
nsuing degranulation.
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ACE and Chymase in Stenotic Aortic Valves November 2, 2004:1859–66In the present study, we sought to determine whether
CE and MC chymase are produced locally in the
alvular tissue and whether the Ang II-forming potential
n stenotic aortic valves is increased.
ETHODS
amples and study population. The stenotic aortic valves
ere obtained from 86 patients aged on average 67 years
range 39 to 82 years) undergoing valve replacement sur-
ery. All had pure AS in that patients with more than mild
ortic or mitral regurgitation were excluded, as were patients
ith any proximal coronary artery stenosis exceeding 50% of
uminal diameter at angiography. Individuals with compli-
ated diabetes and renal insufficiency (serum creatinine
170 mol/l) were also excluded. Twenty percent of the
atients were receiving statins, 22% used either ACE
nhibitors or angiotensin II type 1 receptor (AT-1R) antag-
nists, and 3% received combined therapy consisting of a
tatin and ACE inhibitors or an AT-1R antagonist. The
verage aortic valve area at cardiac catheterization was 0.67
m2 (range 0.30 to 1.1 cm2). At surgery, 72 valves were
ricuspid, 13 were bicuspid, and 1 valve had four cusps. The
ontrol valves were obtained from patients undergoing
ardiac transplantation owing to dilated (n  8) or ischemic
n  1) cardiomyopathy or from organ donors without
ardiac disease whose hearts could not be used as grafts (n
). Of the nine patients undergoing transplantation, seven
ad been on ACE inhibitor therapy for prolonged periods.
he protocol was approved by the ethics committee of
elsinki University Central Hospital, and the participating
atients gave their informed consent to the study.
utoradiography of ACE and AT-1R. Sections of frozen
ortic valves (20 m thick) of 11 randomly selected patients
nd 11 control subjects were cut on a cryostat at17°C, and
haw mounted onto Super Frost Plus slides (Menzel-Glaser,
ermany). For ACE autoradiography, a tyrosyl residue of
he ACE inhibitor lisinopril, compound 351A (Merck
harp & Dohme Research Laboratories, West Point, Penn-
ylvania), was iodinated by the chloramine T method and
urified on a SP-Sephadex C-25 column (Pharmacia,
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
Ang II  angiotensin II
AS  aortic stenosis
AT-1R  angiotensin II type 1 receptor
AT-2R  angiotensin II type 2 receptor
DNA  deoxyribonucleic acid
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
LDL  low-density lipoprotein
MC  mast cell
mRNA  messenger ribonucleic acid
RT-PCR  reverse transcription-polymerase chain
reactionockville, Maryland). For quantitative in vitro ACE auto-adiography, a previously described technique (20) was
pplied. Briefly, aortic valve sections were pre-incubated for
5 min at room temperature in 10 mM sodium phosphate
uffer, pH 7.4, containing 150 mM NaCl and 0.2% bovine
erum albumin, followed by incubation for 1 h at room
emperature in a fresh volume of the same buffer containing
.3 Ci/ml of 125I-351A. Non-specific binding was deter-
ined in parallel incubations in the same buffer containing
mM Na2-ethylenediaminetetraacetic acid. After incuba-
ion, the sections were washed four times for 1 min in
ce-cold buffer without bovine serum albumin and 125I-
51A to remove unbound radioligand, and dried under a
tream of cool air. For quantification of ACE binding, the
ections were placed on a Fuji Imaging Plate BAS-TP2025
Tamro, Finland) for 3 h. The optical densities were
uantified by an AIDA computer image analyzing system
AIDA 2D densitometry, Paris, France) coupled to a
ujifilm BAS-5000 phosphoimager (Tamro). Specific bind-
ng was calculated as total binding minus non-specific
inding. To study if angiotensin receptors also are upregu-
ated in stenotic aortic valves, we performed in vitro auto-
adiography of AT-1R and angiotensin II type 2 receptor
AT-2R) from frozen sections using a previously described
ethod (21).
ompetitive reverse-transcription polymerase chain re-
ction (RT-PCR). Total ribonucleic acid (RNA) was iso-
ated from the aortic valves of 84 patients (RNA isolation
rom two patient samples failed because of a high degree of
alcification) and 11 control subjects. Isolation was per-
ormed with an ultra-pure TRIzol reagent (Gibco BRL,
aithersburg, Maryland), and a RNeasy Fibrous Tissue
ini Kit (Qiagen) including deoxyribonuclease digestion
Qiagen, Hilden, Germany); 0.25 g of purified total RNA
as transcribed into complementary deoxyribonucleic acid
ith a Superscript TM pre-amplification system (Gibco
RL). The primers were as follows: ACE: 5=-GGTGCCT-
TCCCAGACAAGC (S), 5=-AGAGCTGGTCCAT-
GTGACC (AS); glyceraldehyde-3-phosphate dehydro-
enase (GAPDH): 5=-ACCACAGTCCATGCCATCAC
S), 5=-TCCACCACCCTGTTGCTGTA (AS); chymase:
=-TCCCACCTGGGAGAATGTGC (S), 5=-TGCA-
CCGACCGTCCATAGG (AS).
The competitor deoxyribonucleic acid (DNA) for ACE
as obtained by insertion of a 380 bp external DNA
ragment into the SacI site and for chymase by insertion of
344-bp external DNA fragment into the ApaI site. The
olymerase chain reaction product was verified, by DNA
equencing, to represent the corresponding target. The use
f equal amounts of messenger ribonucleic acid (mRNA) in
he RT-PCR assays was confirmed by analyzing the expres-
ion levels of GAPDH (data not shown). The polymerase
hain reaction products were quantified with a Gel Doc
000 gel documentation system (Bio-Rad), and the loga-
ithm of the competitor-to-target ratio was plotted against
he logarithm of the competitor DNA molecules (22).To correct for potential variances in mRNA extraction
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November 2, 2004:1859–66 ACE and Chymase in Stenotic Aortic Valvesnd reverse-transcription efficacy between samples and for
ariances in polymerase chain reaction pipetting, the com-
etitive RT-PCR assay was standardized to the expression
evel of GAPDH.
mmunohistochemistry of MCs, ACE, T lymphocytes,
nd macrophages. Frozen aortic valves were divided into
our sections from base to tip, and immunohistochemistry of
Cs was performed in all sections (of 86 patients and 11
ontrol subjects) by a commercially available monoclonal
nti-tryptase antibody (clone AA1, Dako, Glostrup, Den-
ark) at a concentration of 0.11 g/ml. A randomly
igure 1. Local angiotensin-converting enzyme (ACE) and angiotensin I
CE autoradiography images of a normal and a stenotic aortic valve. (B)
tenotic (n  11) aortic valves. (C) Quantitative analysis of AT-1R autorad
ortic valves (n  11) compared with control valves (n  11). Results areelected subpopulation of the stenotic valves (11 patients) wnd all normal valves were also stained with monoclonal
nti-chymase antibody (concentration 10 g/ml, Serotec,
anar, Germany) for chymase-positive MCs. Briefly, after
ncubation in methanol for 10 min, the endogenous perox-
dase activity was blocked by incubation in 2% H2O2 in
ethanol for 30 min. The slides were washed in phosphate-
uffered saline, incubated with blocking serum (normal
orse serum for tryptase, and rabbit serum for chymase;
ectastain Elite Kit, Vector Laboratories, Burlingame, Cal-
fornia) for 30 min and then with primary antibody diluted
n blocking serum overnight. After washing of the sections
1 receptor (AT-1R) activities are increased in stenotic aortic valves. (A)
ntitative analysis of ACE autoradiography levels in normal (n  11) and
phy showed 5.5-fold increase (p  0.05) in the level of AT-1R in stenotic
values  SD. *p  0.05; ***p  0.001.I type
Qua
iograith phosphate-buffered saline, a biotinylated secondary
a
r
(
b
b
F
acid (mRNA) expression is higher in stenotic aortic valves (n  84) than
in control valves (n  11). Individual data points and medians are shown.
F
i
1
Figure 4. Mast cell (MC) numbers are higher in stenotic than in normal aortic v
normal (n 11) aortic valves. (B) The number of chymase-containing MCs in st
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ACE and Chymase in Stenotic Aortic Valves November 2, 2004:1859–66ntibody (Vectastain Elite Kit) against tryptase or a horse-
adish peroxidase-F(ab)-conjugated secondary antibody
Serotec) against chymase was applied for 30 min, followed
y washes with phosphate-buffered saline and avidin-
iotin-peroxidase conjugate (ABC Elite, Vector Laborato-
igure 3. Chymase messenger ribonucleic acid (mRNA) expression is
ncreased in stenotic aortic valves (n  84) over that of control valves (n 
1). Lines denote medians.
2igure 2. Angiotensin-converting enzyme (ACE) messenger ribonucleicalves. (A) The total number of MCs (cells/mm ) in stenotic (n  86) and
enotic (n 11) and normal (n 11) aortic valves. Lines indicate medians.
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November 2, 2004:1859–66 ACE and Chymase in Stenotic Aortic Valvesies) for 30 min. Standard peroxidase enzyme substrate,
-amino-9-ethylcarbazole was added, and the sections were
ounterstained with hematoxylin (Mayer, Merck, Darm-
tadt, Germany) and mounted. The exact numbers of
ryptase-positive and chymase-positive MCs in each section
ere counted by light microscopy, and the area of each
ection was measured by computer-assisted morphometry
Image-Pro Plus, version 4.5). For the purpose of determin-
ng the degree of MC activation, the number of degranu-
ated MCs in relationship to the total number of valvular
Cs was calculated in 11 randomly selected stenotic and in
ll 11 control aortic valves. The ACE was detected immu-
ohistochemically with polyclonal antibodies (concentration
g/ml, Santa Cruz, Santa Cruz, California), and macro-
hages and T lymphocytes were detected with monoclonal
ntibodies HAM-56 (Dako) and CD3 (Dako) at concen-
rations of 0.7 and 2.4 g/ml, respectively.
tatistics. Statistics were calculated with the SPSS soft-
are, version 11.0. The data presented in Figure 1 were
nalyzed using the Student t test, and the results are
igure 5. Immunostaining of mast cells (MC) in normal (A) and stenotic
B) aortic valves. (A) Section of a normal aortic valve showing a few MCs
arrows) in a subendothelial location. (B) Section of a stenotic aortic valve
emonstrating MC distribution throughout the leaflet and association of
Cs with the calcified lesions of the valves (one arrow).xpressed as the mean value and SD. When analyzing the cata presented in other figures (Figs. 2 to 6), the Mann-
hitney U test served to calculate differences between the
roups. Individual data points and medians are shown in the
gures. Differences were considered statistically significant
hen p  0.05. For correlations, Spearman’s correlation
oefficients were calculated.
ESULTS
utoradiography of active ACE and AT-1R in aortic
alves. Autoradiography of aortic valves with a radiolabeled
nhibitor of ACE (351A) showed the presence of enzymat-
cally active ACE in normal valves (Fig. 1A, left panel).
owever, in stenotic valves, the level of enzymatically active
CE was significantly increased (Fig. 1A, right panel, and
ig. 1B) and distributed throughout the aortic valve leaflet.
uantification of the autoradiographic images revealed
hree-fold increase in ACE activity in stenotic valves com-
ared with that of control valves (p  0.001) (Fig. 1B).
Quantitative analysis of AT-1R autoradiography showed
5.5-fold increase (p  0.05) in the level of AT-1R in
tenotic aortic valves as compared with control valves
Fig. 1C). The levels of AT-2R were below the detection
imit both in control and in diseased valves.
ompetitive RT-PCR of ACE and chymase. The RT-
CR analyses revealed that ACE is expressed locally in both
ormal and stenotic aortic valves and that the expression of
CE mRNA was significantly higher in stenotic valves than
n control valves (3.8-fold, p  0.001) (Fig. 2). In the
ontrol valves, the ACE mRNA expression was similar in
he cardiomyopathy patients who had been on chronic ACE
nhibition as in patients free of cardiovascular disease or
edication. Furthermore, in stenotic aortic valves, the
xpression levels of ACE mRNA did not differ significantly
hether ACE inhibitor or AT-1R antagonist therapy was
resent or absent.
In addition to ACE, chymase, the other potential Ang
I-forming enzyme, was also expressed in both normal and
tenotic aortic valvular tissue. The expression levels of
hymase mRNA were highly upregulated in stenotic versus
ormal aortic valves (7.6-fold, p  0.001) (Fig. 3). There
ere no significant differences in chymase mRNA expres-
ion levels between the patients or control subjects with or
ithout ACE inhibitor or AT-1R antagonist treatment. No
tatistically significant differences in the expression levels of
CE and chymase were found between bicuspid and
ricuspid aortic valves. Moreover, the expression levels of
CE and chymase did not correlate with the age of the
atients or control subjects. A positive correlation appeared
etween the expression levels of chymase and ACE mRNAs
r  0.325; p  0.001).
mmunohistochemical detection of MC-specific tryptase
nd chymase. Immunohistochemistry using anti-tryptase
ntibodies, a specific marker of MCs, revealed that MCs are
resent in aortic valves, and that their number is signifi-
antly increased in stenotic valves over that of control valves
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ACE and Chymase in Stenotic Aortic Valves November 2, 2004:1859–66Fig. 4A). The degree of MC infiltration was similar in
icuspid and tricuspid stenotic aortic valves. The accumu-
ation of MCs in stenotic valves was evident in all four
ections, that is, from leaflet base to tip. The difference in
C distribution density between the stenotic and control
alves was, however, most obvious in the two middle
ections of the valves (5.1 [0.6 to 41.9] MCs/mm2 vs. 0.9 [0
o 2.4] MCs/mm2, median [range], p  0.001)
Fig. 4A). Immunohistochemistry using anti-chymase anti-
odies showed that the MCs present in stenotic and control
ortic valves also contain chymase (3.6 [2.5 to 16.5] vs. 1.5
0.4 to 2] chymase-positive MCs/mm2, p  0.001) (Fig.
B). In control valves, the MCs (reddish-brown staining)
ere localized to the subendothelial space, whereas in
tenotic valves, they were distributed throughout the leaflet
nd were associated especially with the calcified lesions of
he stenotic valves (Fig. 5). The degree of MC degranula-
ion, a prerequisite for chymase secretion and action, was
nhanced in stenotic valves, appearing as an extracellular rim
f granules and granule mediators around the activated
Cs (Fig. 6B). In contrast, most of the MCs present in
ormal valves were intact, that is, not degranulated (Fig.
A). In stenotic leaflets, the proportion of MCs activated
as 75% (range, 60% to 83%), whereas in normal valves
nly 9 (0% to 19%) of the MCs showed signs of activation
igure 6. A resting mast cell (MC) in a control valve (A) and an activated
egranulation (i.e., activation) in normal (n  11) and stenotic (n  11)nd degranulation (p  0.001) (Fig. 6C). ommunohistochemical detection of macrophages, T lym-
hocytes, and ACE. Immunohistochemistry of both mac-
ophages and T lymphocytes showed a higher number of
hese inflammatory cells in stenotic valves than in control
alves (data not shown), consistent with previous findings
1–3,23). Immunohistochemistry of ACE and macrophages
n adjacent sections of an aortic valve showed that ACE and
acrophages colocalized in the valvular tissue (Figs. 7A and
B). The specificity of the polyclonal goat anti-ACE
ntibody was verified by substituting for the primary anti-
ody with an irrelevant goat isotype-specific immunoglob-
lin G (Fig. 7C).
ISCUSSION
he present study is the first to reveal that aortic valves
ontain two parallel Ang II-forming enzyme systems: ACE
nd MC-derived chymase, both of which are upregulated in
tenotic valves. The presence of ACE in stenotic aortic
alves has been recently demonstrated by O’Brien et al. (11),
ut until our work, no local production of ACE has been
emonstrated in the valvular tissue. Angiotensin II, the
nzymatic product of angiotensin I degradation by ACE
nd chymase, has a number of proinflammatory and profi-
rotic effects that potentially contribute to the pathogenesis
cell in a stenotic aortic valve (B). (C) Quantification of the degree of MC
valves. Lines denote medians.mastf calcific aortic valve disease. These include its function as
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November 2, 2004:1859–66 ACE and Chymase in Stenotic Aortic Valveschemotactic factor for monocytes (13,14) as well as its
apacity to enhance collagen synthesis by stimulating trans-
orming growth factor-beta (16). The assertion of ACE-
nduced tissue fibrosis in stenotic aortic leaflets is supported
y the finding in the myocardium of patients with AS
igure 7. Adjacent sections of an aortic valve showing colocalization
arrows) of macrophages (A) and angiotensin-converting enzyme (ACE)
B). Control staining with unspecific goat immunoglobulin G shows no
mmunoreactivity (C).emonstrating increased collagen and fibronectin expression bn parallel with activation of the cardiac renin-angiotensin
ystem (24).
The presence of MCs in aortic valves, and in particular,
heir high number in the calcified areas of the stenotic
eaflets, is an intriguing, novel finding. Moreover, a striking
ontrast existed between normal and stenotic valves, in that
he former contained only a few resting MCs, whereas the
atter showed numerous MCs in an activated, degranulated
tate. Activated MCs are present in atherosclerotic plaques
f human coronary arteries, where they promote foam cell
ormation and may trigger degradation of the extracellular
atrix and plaque rupture (25–27). Upon activation, MCs
re capable of releasing a number of proinflammatory and
rofibrotic mediators, such as tumor necrosis factor-alpha
nd transforming growth factor-beta (28–30). The presence
f activated and degranulated MCs in the fibrotic lesions of
he aortic valves suggests that they may participate in the
nduction of fibrosis and calcification with ensuing valve
tiffening. Thus, both chymase and tryptase, by generating
ng II and inducing collagen synthesis (28–30), may act as
rofibrotic mediators in the stenotic valves.
Currently, there exists no approved pharmacologic treat-
ent for aortic valve stenosis, the inevitable outcome of the
isease being valve replacement surgery. Present and previ-
us findings raise the possibility that the process of AS,
eing a chronic inflammatory process, might be attenuated
y therapeutic interventions aiming at inhibiting the activity
f ACE and blocking AT-1R before the late-stage pathol-
gy of the disease, such as calcification, has become mani-
est. The use of AT-1R antagonists, which block Ang
I-mediated effects irrespective of the Ang II-generating
nzyme system, may appear as the most feasible approach.
nother fascinating class of future therapies involves MC
tabilizers or specific inhibitors for chymase and tryptase,
hich may also indirectly reduce the synthesis and secretion
f MC-derived profibrotic molecules and suppress collagen
ynthesis independently of Ang II (31). In addition to the
DL-lowering effects of statins (i.e., less ACE-containing
DL particles entering aortic leaflets [11]), their pleiotropic
nti-inflammatory effects may also be of therapeutic benefit
n the treatment of AS. Indeed, recent retrospective clinical
rials have demonstrated less progression of AS in patients
n statin therapy. Because in the present study, the medi-
ation was not part of the study design, we were unable to
raw any conclusions regarding the effects of medical
herapy on AS. Large, randomized, and well-controlled
linical trials are needed to evaluate whether the novel
harmaceutical approaches will prevent the progression
f AS.
tudy limitations. We document here the upregulation of
wo separate Ang II-producing systems, ACE and chymase,
n stenotic aortic valves but cannot provide information on
heir relative contribution to the local formation of Ang II.
oreover, the actual role of Ang II in the stenotic valves
emains to be shown. Although in this study (including
oth patients and control subjects) the ACE or chymase
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ACE and Chymase in Stenotic Aortic Valves November 2, 2004:1859–66RNA expression levels did not differ significantly between
he patients with or without ACE inhibitor or AT-1R
ntagonist treatment, we cannot fully exclude the possibility
hat the results may have been affected by ACE inhibitor or
T-1R antagonist therapy.
eprint requests and correspondence: Dr. Petri T. Kovanen,
ihuri Research Institute, Kalliolinnantie 4, FIN-00140 Hel-
inki, Finland. E-mail: petri.kovanen@wri.fi.
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